805 F.3d 1112
Fed. Cir.2015Background
- Cubist owns five follow-on patents related to daptomycin (one compound patent — the ’071 reissue — two dosing patents — ’967 and ’689 — and two purity/purification patents — ’238 and ’342). Hospira sought FDA approval to market a generic daptomycin product, triggering suit under the Hatch‑Waxman framework.
- The ’071 patent originally contained a structural diagram misidentifying the stereochemistry of an asparagine residue as L‑Asn; the compound described elsewhere in the specification (and known by Lilly’s code LY146032) was daptomycin, which actually contains D‑Asn. Cubist obtained a PTO certificate of correction replacing L‑Asn with D‑Asn in the formula diagram.
- The district court found the certificate of correction valid, held asserted claims 18 and 26 of the ’071 patent not invalid and infringed by Hospira; but invalidated asserted claims of the four other patents for anticipation/obviousness.
- Hospira appealed contesting the certificate of correction (scope broadening), written‑description sufficiency, and reissue/recapture issues for the ’071 patent; Cubist cross‑appealed the invalidity rulings on the dosing and purity patents.
- The Federal Circuit affirmed: upheld the certificate of correction and the ’071 claims (including written‑description and recapture rulings), and affirmed invalidity of the dosing and purity patents for obviousness.
Issues
| Issue | Plaintiff's Argument (Cubist) | Defendant's Argument (Hospira) | Held |
|---|---|---|---|
| 1) Validity/effect of PTO certificate of correction to change L‑Asn to D‑Asn in ’071 | The structural diagram was a clerical/mischaracterization error; the specification (LY146032, A‑21978C references, fermentation source) always pointed to daptomycin (D‑Asn), so correction merely fixed a minor error and did not broaden claims | The correction broadened claim scope because the original diagram identified a different compound (L‑Asn variant); the PTO erred and the claims should be limited to the L‑Asn variant | Certificate of correction upheld. The court deferred to district court fact findings that the specification and other disclosures showed claim coverage of daptomycin; change was a minor correction not broadening scope. |
| 2) Written‑description sufficiency for ’071 after correction | Specification (code name, A‑21978C/fermentation disclosures) conveyed possession of daptomycin despite structural mistake; satisfies §112 | Specification lacked description of D‑Asn structure and thus fails §112 written‑description for corrected claims | Written description sufficient; district court factual finding that skilled artisan would understand inventors possessed the fermentation product (daptomycin) was not clearly erroneous. |
| 3) Reissue/recapture rule for ’071 (did reissue impermissibly recapture surrendered subject matter) | Reissue claims (18,26) are narrower than original claim 24 (require Formulas 1 and 2), and prosecution shows claim 24 was cancelled for indefiniteness not to avoid prior art, so no recapture | Reissue broadened original patent to cover subject matter surrendered during prosecution | Recapture rule did not apply; claims were not broader in the relevant sense and prosecution history showed withdrawal for indefiniteness, not to avoid prior art. |
| 4) Obviousness of dosing and purity patents | Dosing: Cubist argued claimed regimens solved toxicity problem and secondary considerations (long‑felt need, commercial success) show nonobviousness. Purity: Cubist argued novel process/unexpected micelle behavior produced high purities not taught by prior art. | Dosing: Prior art (Woodworth article, ’226 patent, known properties of daptomycin and aminoglycosides) taught 4–6 mg/kg dosing and once‑daily or longer intervals; obvious to try/expectation of success. Purity: Micelle filtration and ion‑exchange chromatography were known; combining them to remove saponins/endotoxins and obtain high purity would have been obvious. | Affirmed invalidity for obviousness of all asserted claims of the dosing and purity patents. District court’s findings on prior art teachings, predictability, and weighing of secondary considerations were upheld. |
Key Cases Cited
- Superior Fireplace Co. v. Majestic Prods. Co., 270 F.3d 1358 (Fed. Cir. 2001) (certificate‑of‑correction minor‑character/breadth precedent)
- Regents of Univ. of N.M. v. Knight, 321 F.3d 1111 (Fed. Cir. 2003) (chemical structure diagrams are descriptive, not dispositive of claim scope)
- Bayer CropScience AG v. Dow Agrosciences LLC, 728 F.3d 1324 (Fed. Cir. 2013) (distinguishing claim construction/functional‑claim issues from certificate‑of‑correction context)
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (written‑description requirement standard)
- In re Wallach, 378 F.3d 1330 (Fed. Cir. 2004) (written‑description limits when applicants possess only partial sequence/structure)
- Pannu v. Storz Instruments, Inc., 258 F.3d 1366 (Fed. Cir. 2001) (recapture rule principle)